Acute Leukemia — Trials

Acute Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,259
Recruiting: 759
Ph III recruiting: 70
Growth YoY: 0%
Industry share: 16%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 36.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (718)

clinicaltrialsPublishedShowing 1–50 of 345 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03739814	Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia	recruiting	Phase 2	84	National Cancer Institute (NCI)NIH	2	Sep 29, 2026	clinicaltrials
NCT06917911	Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)	recruiting	Phase 2	162	National Cancer Institute (NCI)